BlackRock Discloses Passive Stake in PDS Biotechnology Corp
Ticker: PDSB · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investing, biotechnology, form-13g
TL;DR
**BlackRock owns a chunk of PDS Biotech, but they're just holding, not trying to run the show.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in PDS Biotechnology Corp's Common Stock. This filing indicates BlackRock's passive ownership, meaning they are not seeking to influence management. For investors, this signals that a large, institutional investor sees value in PDS Biotechnology, potentially lending credibility to the stock, but also means a large block of shares could be sold without prior notice if BlackRock changes its investment strategy.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant, passive stake in PDS Biotechnology, which can be seen as a vote of confidence but also represents a large block of shares that could be traded.
Risk Assessment
Risk Level: low — The filing indicates a passive stake by a large institutional investor, which generally doesn't pose an immediate risk to the company's operations or stock price.
Analyst Insight
Investors should note BlackRock's passive stake as a potential signal of institutional interest in PDS Biotechnology, but understand it doesn't imply active management involvement or a guaranteed future price movement.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- PDS Biotechnology Corp (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G
FAQ
What is the purpose of an SC 13G filing?
An SC 13G filing is used by institutional investors, like BlackRock Inc., to report beneficial ownership of more than 5% of a company's stock when they hold the shares passively, meaning they do not intend to influence or control the company's management or policies, as indicated by the selection of Rule 13d-1(b) in this filing.
Which company is the subject of this SC 13G filing?
The subject company of this SC 13G filing is PDS Biotechnology Corp, identified by CIK 0001472091 and CUSIP Number 70465T107.
Who is the reporting person in this SC 13G filing?
The reporting person in this SC 13G filing is BlackRock Inc., identified by CIK 0001364742.
What was the 'Date of Event Which Requires Filing of this Statement' for this SC 13G?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as stated in the filing.
What type of securities are covered by this filing?
This filing covers 'Common Stock' of PDS Biotechnology Corp, as specified under the 'Title of Class of Securities' section.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding PDS Biotechnology Corp (PDSB).